About Us

An attorney by training, Mollie Roth is the Managing Partner of PGx Consulting, which she started in 2010 to provide customized, personalized medicine specific business services to growing life sciences and biotech companies in the personalized medicine space. By combining her expertise in business development, law and communications, Mollie is able to provide highly customized, cost effective solutions to her clients.

Prior to the launch of PGx, Mollie was Chief Operating Officer for Diaceutics, where she was responsible for day-to-day operations as well as overseeing the strategic development and execution of the company’s corporate and product plans, created a strategic marketing and communications plan, directed the strategic and operational leadership of business development and sales efforts as well as leading the company’s thought leadership in the personalized medicine space.

Prior to joining Diaceutics in 2007, Mollie was an attorney in private practice focused on patent and product liability litigation on behalf of the pharmaceutical industry for Kaye Scholer in New York, New York and Nixon Peabody in Washington, DC. While at Nixon Peabody, Mollie created a specialization in pharmacogenomics, speaking to members of the pharmaceutical and venture capital industries on risk management issues relating to potential litigation liabilities in the personalized medicine space.

Prior to attending law school, Mollie was a research scientist at Oregon State University’s College of Pharmacy looking at the role of amino acids in the body’s regulation and mediation of pain.

Mollie holds a B.A. in neuropsychopharmacology from Rutgers University and a J.D. from Vermont Law School, and anticipates presently completing her L.LM in Biotechnology and Genomics from the Sandra Day O’Connor College of Law at Arizona State University. Mollie also served as a Visiting Faculty Fellow in the law school’s Center for the Study of Law, Science, & Technology focused on research relating to the intersection of law and personalized medicine as well as teaching several related courses. She currently sits on the Board of the Center for Law, Science and Innovation.

Mollie’s interest in personalized medicine was sparked by a serendipitous 10-day sailing adventure in 1999 where she was part of the crew delivering Dr. Craig Venter’s 95’ Freres designed sloop, Sorcerer I, from Annapolis, MD to St. Bart’s in the Caribbean. During that trip, Dr. Venter, who was then less than one year away from announcing the results of his Human Genome Project, discussed how sequencing of the human genome would revolutionize the future of drug development. Mollie wisely took notes.